Drug class
Prolactin Inhibitors
Prolactin inhibitors are a functional class of endocrine medications, predominantly consisting of dopamine D2-receptor agonists such as cabergoline and bromocriptine, that suppress the synthesis and secretion of prolactin from the anterior pituitary gland. Read more about Prolactin Inhibitors
19 drugs in this class 16 manufacturers
Drugs in Prolactin Inhibitors
BROMOCRIPTINE MESYLATE
CABERGOLINE
CABERGOLINE
BROMOCRIPTINE MESYLATE
BROMOCRIPTINE MESYLATE
CABERGOLINE
BROMOCRIPTINE MESYLATE
BROMOCRIPTINE MESYLATE
Prolactin inhibitors are a functional class of endocrine medications, predominantly consisting of dopamine D2-receptor agonists such as cabergoline and bromocriptine, that suppress the synthesis and secretion of prolactin from the anterior pituitary gland.
By stimulating pituitary dopamine receptors, these agents mimic endogenous hypothalamic dopamine, which serves as the primary physiological inhibitor of prolactin release.
They are principally indicated for the management of hyperprolactinemic disorders, including prolactin-secreting pituitary adenomas (prolactinomas), galactorrhea, amenorrhea, and related ovulatory or fertility dysfunctions, as well as the physiological suppression of postpartum lactation.
-
nih.gov
Prolactin inhibitors are a functional class of endocrine medications, predominantly consisting of dopamine D2-receptor agonists such as cabergoline and bromocriptine, that suppress the synthesis and secretion of prolactin from the anterior pituitary gland They are principally indicated for the management of hyperprolactinemic disorders, including prolactin-secreting pituitary adenomas (prolactinomas), galactorrhea, amenorrhea, and related ovulatory or fertility dysfunctions, as well as the physi...
-
drugs.com
Prolactin inhibitors are a functional class of endocrine medications, predominantly consisting of dopamine D2-receptor agonists such as cabergoline and bromocriptine, that suppress the synthesis and secretion of prolactin from the anterior pituitary gland
-
cetaf.org
By stimulating pituitary dopamine receptors, these agents mimic endogenous hypothalamic dopamine, which serves as the primary physiological inhibitor of prolactin release
-
scbt.com
By stimulating pituitary dopamine receptors, these agents mimic endogenous hypothalamic dopamine, which serves as the primary physiological inhibitor of prolactin release
-
drugs.com
They are principally indicated for the management of hyperprolactinemic disorders, including prolactin-secreting pituitary adenomas (prolactinomas), galactorrhea, amenorrhea, and related ovulatory or fertility dysfunctions, as well as the physiological suppression of postpartum lactation
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.